50 results about "Fibronectin binding" patented technology

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnba and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

The present invention relates to new recombinant DNA-molecules comprising nucleotide sequences of S. dygalactiae encoding for at least one protein or polypeptide having fibronectin binding property.

Described are modified submucosa and other extracellular matrix materials incorporating an amount of bound, exogenous fibronectin. Further described are such materials also having an amount of exogenous heparin bound to the exogenous fibronectin, and also potentially an amount of an exogenous bioactive material, such as a growth factor, bound to the exogenous heparin. Such materials may be used in methods for the treatment of wounds in patients.

Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.

The present invention relates to a new fibronectin binding protein from E. coli in the form of a curli pili. a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from E. coli coding for a protein or polypeptide having fibronectin binding properties. (FIG. 4).

Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

The invention belongs to the field of epidemiology and sanitation tests, and relates to a PCR quick detection kit for quickly detecting streptococcus equi subsp zooepidemicus and a PCR quick detection method. Particularly, the kit of the invention comprises three pairs of primers which are aimed at M-like proteins (SzP), fibronectin binding proteins (Fnz), superoxide dismutase A (SodA) coding gene respectively and specifically, so the kit can detect the three virulence factors of the streptococcus equi subsp zooepidemicus at the same time. The multiplex PCR detection method is quick and simple, can directly detect pathologic materials, avoids a normal complex process of bacteria isolation, cultivation and biochemical identification, reduces detection time and simplifies operation to allow for skillful use after simple training. The kit is high in sensitivity and can detect micro pathogen. And the kit is high in specificity and can distinguish streptococcus equi subsp zooepidemicus from other kinds of streptococcus without any cross reaction.

An isolated, altered fibronectin-binding protein (Fnb) of S. aureus having at least one mutation in an amino acid selected from residues corresponding to Gln103, Gln105, Lys157, Lys503, Lys620, Lys702, Lys762, Gln783 and Gln830 of FnbA of S. aureus strain ATCC49525 is described. Replacement of these reactive residues within the fibronectin-binding protein renders this protein less capable than wild-type Fnb of covalently cross-linking with fibronectin and fibrin. The altered fibronectin-binding protein effectively interferes with adhesion of S. aureus to fibronectin and fibrin, and therefore, an immunogenic composition comprising such altered Fnb exhibits improved immunogenic properties and is safer to use.

The invention discloses an application of honokiol in preparing medicines for inhibiting staphylococcus biofilms. Drug susceptibility test is utilized to detect the inhibiting effect of honokiol respectively on floating bacteria of staphylococcus aureus and biofilms, and the inhibiting effect of honokiol is further verified by drawing a killing curve and adopting a crystal violet semiquantitative method. Furthermore, the influence on polysaccharide intercellular adhesion (PIA) synthesis and extracellular DNA (eDNA) release and investigations on the transcriptional level of coding fibronectin-binding protein genes fnbA and fnbB indicate that the honokiol has an excellent effect for inhibiting growth of staphylococcus aureus biofilms.

Provided herein are chimeric antigen receptors (CARs) for binding with a target antigen, comprising at least one antigen specific targeting region comprising a fibronectin type 3 (FN3) domain polypeptide. Provided herein are multispecific chimeric antigen receptors for binding with two or more target antigens, comprising at least two antigen specific targeting regions comprising a fibronectin type3 domain polypeptide. Also provided herein are compositions and methods of treatment relating to the use of subject CARs of the invention.

The invention discloses a Mycoplasma bovis alcohol dehydrogenase gene, having a nucleotide sequence shown as SEQ ID NO: 1. The invention also discloses a protein coded by the Mycoplasma bovis alcohol dehydrogenase gene; the protein has an amino acid sequence shown as SEQ ID NO: 2 and belongs to the technical field of prevention and treatment of animal infectious diseases and biology. The protein, as a recombinant protein herein, has alcohol dehydrogenase activity, can attach to EBLs (embryonic bovine lung cells), can combine with bovine Fn (fibronectin), has good immunogenicity and reactogenicity, is a virulence-related protein of Mycoplasma bovis, and has a good application prospect in the research on pathogenesis of Mycoplasma bovis, and the research and development of vaccines and diagnostic reagents.

The invention discloses a recombinant fusion protein HF2 which is composed of staphylococcus aureus alpha hemolysin (H1a) and a fibronectin binding protein (FNBA) segment, wherein the H1a and the FNBA are fused through a linker peptide. The protein can be used for preparing subunit vaccines and relevant detection kits capable of resisting infections of the methicillin-resistant staphylococcus aureus (MRSA). A gene engineering technology is used to recombine and express the fused protein. The method has high expression level, facilitates separation and purification and has high efficiency and safety. Animal experiment results show that the recombinant fusion protein HF2 can effectively stimulate a body to produce relatively high humoral immune response and good immune protection effect.

Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.

The present invention relates to a composition comprising at least one fibronectin binding protein, and / or at least one a truncated fibronectin binding protein and / or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrixcomplex and / or liposome and / or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and / or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and / or an Iscom matrixcomplex and / or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual.

The present invention is directed to various uses of fibronectin binding proteins or polypeptides for treating and preventing fibrosis and fibrosis related conditions. The fibronectin binding proteins and polypeptides are also useful for treating conditions associated with vascular remodeling and cardiac dysfunction.

The invention provides multivalent fibronectin-integrin binding compositions and methods of use thereof. In certain embodiments, the invention provides peptide compositions that include at least two fibronectin binding peptides coupled together as a cancer therapeutic or a diagnostic tool.

Methods and compositions for reducing the incidence of C. jejuni bacteria infections in poultry and in humans and other animals are formulated to include C. jejuni antigens, and particularly CadF, FlpA and FlaA. The antigens may be provided in the form of polypeptides or by hosts that produce the antigens. Fibronectin binding proteins of C. jejuni may also be used to deliver substances of interest to humans and other animals.

A method for the inhibition of the binding of alpha4beta1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which alpha4beta1 is involved.

The present invention relates to a composition comprising at least one fibronectin binding protein, and / or at least one a truncated fibronectin binding protein and / or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrix complex and / or liposome and / or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and / or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and / or an Iscom matrix complex and / or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual.

The present invention is directed to various uses of fibronectin binding proteins or polypeptides for treating and preventing fibrosis and fibrosis related conditions. The fibronectin binding proteins and polypeptides are also useful for treating conditions associated with vascular remodeling and cardiac dysfunction.

Provided herein are chimeric antigen receptors (CARs) for binding with a target antigen, comprising at least one antigen specific targeting region comprising a fibronectin type 3 (FN3) domain polypeptide. Provided herein are multispecific chimeric antigen receptors for binding with two or more target antigens, comprising at least two antigen specific targeting regions comprising a fibronectin type 3 domain polypeptide. Also provided herein are compositions and methods of treatment relating to the use of subject CARs of the invention.

The invention provides multivalent fibronectin-integrin binding compositions and methods of use thereof. In certain embodiments, the invention provides peptide compositions that include at least two fibronectin binding peptides coupled together as a cancer therapeutic or a diagnostic tool.

The present invention relates to methods of inhibiting the binding of α4β1 integrin to its receptors such as VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit such binding; pharmaceutically active compositions containing such compounds; and Use of such compounds in the above aspects or in preparations for controlling or preventing disease states in which α4β1 is involved.